An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Fizazi, K. [1 ]
Bono, P. [2 ]
Jones, R. H. [3 ]
Kataja, V. [4 ]
James, N. [5 ]
Garcia, J. [6 ]
Protheroe, A. [7 ]
Vuorela, A. [8 ]
Mattila, L. [8 ]
Mustonen, M. V. J. [8 ]
机构：
[1] Univ Paris, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[2] Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland
[3] Cardiff Univ, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales
[4] Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland
[5] Queen Elizabeth Hosp, Birmingham Univ Hosp NHS, Birmingham B15 2TH, W Midlands, England
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Churchill Hosp, Oxford OX3 7LJ, England
[8] Orion Corp Orion Pharma, R&D, Espoo, Finland
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2853
引用
收藏
页码：S680 / S680
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
    Massard, Christophe
    Penttinen, Heidi M.
    Vjaters, Egils
    Bono, Petri
    Lietuvietis, Vilnis
    Tammela, Teuvo L.
    Vuorela, Annamari
    Nykanen, Pirjo
    Pohjanjousi, Pasi
    Snapir, Amir
    Fizazi, Karim
    EUROPEAN UROLOGY, 2016, 69 (05) : 834 - 840
  • [2] A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).
    Rathkopf, D. E.
    Danila, D. C.
    Slovin, S. F.
    Morris, M. J.
    Steinbrecher, J. E.
    Chen, Y.
    Fleisher, M.
    Larson, S. M.
    Sawyers, C. L.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)
    Massard, Christophe
    Tammela, Teuvo L. J.
    Vjaters, Egils
    Lietuvietis, Vilnis
    Bono, Petri
    Penttinen, Heidi
    Nykanen, Pirjo
    Snapir, Amir
    Mattila, Leena
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
    Fizazi, Karim
    Massard, Christophe
    Bono, Petri
    Jones, Robert
    Kataja, Vesa
    James, Nicholas
    Garcia, Jorge A.
    Protheroe, Andrew
    Tammela, Teuvo L.
    Elliott, Tony
    Mattila, Leena
    Aspegren, John
    Vuorela, Annamari
    Langmuir, Peter
    Mustonen, Mika
    LANCET ONCOLOGY, 2014, 15 (09): : 975 - 985
  • [5] Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.
    Massard, Christophe
    Penttinen, Heidi
    Bono, Petri
    Vjaters, Egils
    Lietuvietis, Vilnis
    Tammela, Teuvo L. J.
    Vuorela, Annamari
    Nykanen, Pirjo
    Pohjanjousi, Pasi
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial
    Bjartell, Anders
    EUROPEAN UROLOGY, 2015, 67 (02) : 348 - 349
  • [7] Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC)
    Garcia, Jorge A.
    Kataja, Vesa V.
    James, Nicholas David
    Jones, Robert Hugh
    Protheroe, Andrew
    Massard, Christophe
    Mattila, Leena
    Mustonen, Mika V. J.
    Aspegren, John
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Barata, Pedro C.
    Cooney, Matthew
    Mendiratta, Prateek
    Tyler, Allison
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1085 - 1092
  • [9] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Pedro C. Barata
    Matthew Cooney
    Prateek Mendiratta
    Allison Tyler
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 1085 - 1092
  • [10] OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC)
    Noguchi, Masanori
    Moriya, Fukuko
    Suekane, Shigetaka
    Matsuoka, Kei
    Arai, Gaku
    Matsueda, Satoko
    Sasada, Tetsurou
    Yamada, Akira
    Itoh, Kyogo
    JOURNAL OF UROLOGY, 2011, 185 (04): : E360 - E361
12345